产品
编 号：F621044
分子式：C54H66Cl2N10O9S2
分子量：1134.2
分子式：C54H66Cl2N10O9S2
分子量：1134.2
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2060573-82-0
产品详情
生物活性：
MT1 is a bivalent chemical probe of BET bromodomains, with an IC50 of 0.789 nM for BRD4(1).
体内研究：
MT1 (44.2 and 22.1 μmol/kg, ip daily, for 14 days) significantly delayed leukemia progression in mice (Mus musculus) compared to JQ1.MT1 exhibits terminal t1/2 of 2.70 h in mice.Animal Model:Leukemia xenograft models.
Dosage:44.2 and 22.1 μmol/kg.
Administration:Intraperitoneally for 14 subsequent days.
Result:Significantly reduced leukemic burden over the course of the study compared to either vehicle or JQ1.
体外研究：
MT1 (100 nM, 24 h) significantly induces apoptosis via caspase-3 and PARP in MV4;11 cells.
MT1 is a bivalent chemical probe of BET bromodomains, with an IC50 of 0.789 nM for BRD4(1).
体内研究：
MT1 (44.2 and 22.1 μmol/kg, ip daily, for 14 days) significantly delayed leukemia progression in mice (Mus musculus) compared to JQ1.MT1 exhibits terminal t1/2 of 2.70 h in mice.Animal Model:Leukemia xenograft models.
Dosage:44.2 and 22.1 μmol/kg.
Administration:Intraperitoneally for 14 subsequent days.
Result:Significantly reduced leukemic burden over the course of the study compared to either vehicle or JQ1.
体外研究：
MT1 (100 nM, 24 h) significantly induces apoptosis via caspase-3 and PARP in MV4;11 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备